Business
IGC Pharma's Principal Scientist Dr. Jagadeesh Rao Receives Best Researcher Award at 11th Annual World Neuroscience Awards
POTOMAC, MD / ACCESS Newswire / July 21, 2025 /IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scientist, Jagadeesh Rao, Ph.D., has been awarded the ...
About this update from Igc Pharma, Inc.
[{"type":"text","content":"POTOMAC, MD / ACCESS Newswire / July 21, 2025 / IGC Pharma, Inc. (NYSE American:IGC) a clinical-stage biopharmaceutical company focused on Alzheimer's disease, today announced that its Principal Scientist, Jagadeesh Rao, Ph.D., has been awarded the Best Researcher Award at the 11th Annual World Neuroscientist Awards.","length":322,"tagName":"p"},{"type":"text","content":"Dr. Rao was selected through a rigorous evaluation by an international panel of academic and industry experts in clinical drug development and neuroscience research. The award recognizes his extensive contributions across neuroscience, psychiatry, neuropharmacology, molecular biology, and biochemistry, underscoring more than 15 years of scientific leadership and innovation in the field.","length":389,"tagName":"p"},{"type":"text","content":""This global recognition of Dr. Rao's accomplishments reinforces IGC Pharma's commitment to scientific excellence and its leadership in advancing novel therapeutics for Alzheimer's disease," said Ram Mukunda, CEO of IGC Pharma. "Dr. Rao's expertise in neuroscience and regulatory science is instrumental to our drug development programs, and this award highlights the caliber of talent driving our mission to deliver effective treatments for patients."","length":488,"tagName":"p"},{"type":"text","content":"Dr. Rao's recent work includes publications on neurobiological alterations in agitation in Alzheimer's disease, as well as studies on epigenetic changes in the frontal cortex of Alzheimer's and bipolar disorder patients. His contributions have been central to the advancement of IGC-AD1, the Company's investigational drug currently in Phase 2 trials for treating agitation in Alzheimer's patients.","length":418,"tagName":"p"},{"type":"text","content":"The World Neuroscientist Awards received over 360 nominations from researchers across 125 countries, making Dr. Rao's selection a noteworthy acknowledgment of the global relevance and quality of his work.","length":208,"tagName":"p"},{"type":"text","content":"About IGC Pharma (dba IGC):","length":27,"tagName":"p"},{"type":"text","content":"IGC Pharma (NYSE American: IGC) is a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's and metabolic disorders. Our lead asset, I...